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Abstract (word count: 247) 
Objectives: Helicobacter pylori (H. pylori) is associated with peptic ulcers and gastric cancer 
and its eradication aims to prevent these conditions. The recommended eradication regimen is 
triple therapy, consisting of a proton pump inhibitor in combination with clarithromycin and 
amoxicillin or metronidazole for 7 days. Yet, other antibiotic regimens are sometimes 
prescribed. We aimed to assess the use of eradication therapy for H. pylori in the Swedish 
population during the last decade.  
Materials and Methods: This population-based study used data from the Swedish Prescribed 
Drug Register. From July 2005 until December 2014, all regimens that can eradicate H. pylori 
were identified and evaluated according to patients’ age and sex and calendar year of 
eradication.  
Results: We identified 157,915 eradication episodes in 140,391 individuals (53.8% women, 
42.6% older than 60 years), who correspond to 1.5% of the Swedish population. The absolute 
number and incidence of eradications decreased over the study period. Overall, 91.0% had 1 
eradication and 0.1% had more than 3. Of all eradications, 95.4% followed the recommended 
regimen, while 4.7% did not. The latter group was overrepresented among individuals aged 
≥80 years (7.8%). Amoxicillin and clarithromycin were most frequently prescribed, while 
metronidazole was rarely used (0.01%). Other prescribed antibiotics were ciprofloxacin 
(2.4%), doxycycline (1.4%), nitrofurantoin (0.7%), norfloxacin (0.5%) and erythromycin 
(0.3%).  
Conclusions: During the last decade in Sweden H. pylori eradication has been frequently 
prescribed, but the incidence of eradication has slowly declined. Most eradications followed 
the recommended regimen, including those occurring after a previous eradication.  
Keywords: Helicobacter pylori, eradication, population-based, epidemiology, Sweden, antibiotics. 
  
Introduction 
Helicobacter pylori (H. pylori) is a bacterium associated with an increased risk of peptic 
ulcers and gastric cancer.[1] Once detected, H. pylori is usually eradicated, mainly to prevent 
the recurrence of ulcers. In parts of Asia, where the prevalence of H. pylori is high, the 
bacterium is also eradicated to prevent gastric cancer, sometimes even in asymptomatic 
individuals.[2] In Sweden, where the prevalence of H. pylori is lower (11%),[3, 4] there is no 
population screening for H. pylori, so eradication is usually restricted to symptomatic patients. 
However, recent consensus states that all individuals with documented H. pylori infection 
should receive eradication.[5] Eradication therapy usually consists of a combination of 2 
antibiotics with a gastric acid inhibitor (most often a proton-pump inhibitor (PPI)), sometimes 
in combination with bismuth compounds. The recommended eradication regimen in Northern 
Europe is triple therapy with a PPI in combination with clarithromycin and amoxicillin or 
metronidazole for 7 days.[5] A treatment alternative with comparable efficacy is bismuth-
containing quadruple therapy, since the addition of bismuth can lead to a 30-40% increase in 
eradication success in areas with high antibiotic resistance.[6] However, bismuth is rarely 
used in Sweden, and many other combinations of antibiotics can also be prescribed.[5] The 
most important reasons to prescribe an alternative regimen are antibiotic resistance and 
unsuccessful previous eradication. Globally, the antibiotic resistance of H. pylori ranges from 
10 to 80% for metronidazole, 1 to 25% for clarithromycin, and less than 1% for 
amoxicillin.[7] In Sweden, antibiotic resistance for H. pylori is lower than average, with an 
estimated 16% for metronidazole, 2% for clarithromycin and 0% for amoxicillin.[8]. These 
numbers are based on studies performed more than a decade ago in Sweden and no recent 
data on antibiotic resistance in H. pylori is available. Although the Swedish guidelines are 
based on the European recommendation for triple therapy, it is unclear to what extent these 
guidelines are followed, in particular after failure of a previous eradication attempt. Therefore, 
the aim of this study was to explore patterns and trends for H. pylori eradication in the entire 
Swedish population.  
  
Materials and methods 
Design 
This was a descriptive study of H. pylori eradication therapy within the Swedish population 
from 1st July 2005 to 31st December 2014. Data were derived from the Swedish Prescribed 
Drug Register, which started on 1st July 2005 and contains information about all prescribed 
and dispensed medications in Sweden. Drugs used only during in-hospitalizations are not 
recorded. The register contains information about the name and code from the Anatomical 
Therapeutic Chemical (ATC) Classification System of the medication, dates of prescription 
and dispensing, patient characteristics, the practice issuing the prescription, the prescriber’s 
profession, and costs. The National Corporation of Swedish Pharmacies directs the data 
collection and each month sends all information to the National Board of Health and Welfare, 
which holds and manages the Swedish Prescribed Drug Register. We used information on 
patients’ age and sex, ATC codes for antibiotics and drugs for peptic ulcers and 
gastroesophageal reflux disease, dates of dispensing, and defined daily dose (DDD) per 
package. The exact prescribed daily dosage and duration was not available and indications for 
prescriptions were not recorded. The register is complete for the whole Swedish population 
(patient identification data are missing in <0.3% of all items).[9] Availability of individual 
information about study participants is enabled by the personal identity numbers given to each 
Swedish resident upon birth or immigration, and used throughout life. The study was 
approved by the Regional Ethical Review Board in Stockholm (2014/1291-31/4), which 
waived informed consent. 
 
Definition of eradication regimens 
An eradication episode of H. pylori was a priori defined as a combination of prescriptions for 
at least 2 different systemic antibiotics (dispensed on the same date) and a PPI within a time 
window of 60 days before or 5 days after antibiotic prescription. The 60-day limit was used to 
capture individuals already using PPIs, e.g. before any H. pylori test results are known, and 
the 5-day limit takes potential temporary non-availability in the pharmacy into account. The 
construction of the cohort is visualised in Figure 1. The prescriptions (with ATC codes) were 
grouped according to the antibiotics prescribed:  
1) “Recommended eradication regimen” consisted of 1 PPI and 2 antibiotics (amoxicillin 
(J01CA04) and/or clarithromycin (J01FA09) and/or metronidazole (J01XD01)), either 
prescribed separately at the same occasion or in a combination package designed specifically 
for H. pylori eradication (A02BD06: esomeprazole, amoxicillin and clarithromycin). 
2) “Alternative eradication regimens” included prescription of a PPI in combination with 2 or 
more different antibiotics of which at least 1 was from the following groups (excluding the 
antibiotics used for recommended eradication): macrolides (J01FA), imidazole derivatives 
(J01XD), tetracyclines (J01AA), fluoroquinolones (J01MA), nitrofuran derivatives (J01XE) 
or rifabutin (J04AB04), possibly in combination with bismuth subcitrate (A02BX05).[5, 10, 
11] To exclude antibiotic combination treatment for indications other than H. pylori 
eradication, we excluded prescription episodes including antibiotics with a dosage for >21 
days (based on the defined daily dosage (DDD) per package) and individuals who received 
≥50 prescriptions for antibiotics during the study period, since these were unlikely to be 
prescribed for H. pylori eradication.  
 
Statistical analyses 
Absolute and relative frequencies of the different eradication regimens and different 
antibiotics were calculated, and stratified by age group (10-year intervals), sex and calendar 
year. The first eradication treatment during the study period for each individual and 
subsequent eradication episodes were analyzed separately. If an individual received ≥4 
eradication episodes during the study period, only the first 3 were evaluated to assure validity, 
since with increasing number of eradication episodes the likelihood of compliance and proper 
use of therapy decreases. Additionally, prescription trends over time were assessed by 
calculating the incidence proportion for each calendar year from 2006 onwards, by dividing 
all prescriptions in 1 year by number of inhabitants in Sweden for the same year. All analyses 
were performed using the statistical software STATA (Stata Corp v 13.0).  
 
  
Results 
Overall eradication cohort 
During the study period (2005-2014), 157,915 prescriptions for H. pylori eradication were 
dispensed to 140,391 individuals. This corresponds to 1.5% of the Swedish population. Of 
these individuals, 53.8% were female, and 42.6% were older than 60 years. A female 
predominance was present in all age groups, but was smaller in the age groups 60 to 79 years 
(Figure 2). Overall, 127,810 individuals (91.0%) received 1 eradication, 9,900 (7.1%) 
received 2 eradications, 1,669 (1.2%) received 3 eradications, and 1,012 (0.1%) received ≥4 
eradications. A second or third eradication was more often seen in individuals aged 40-49 
(18.9%) or 50-59 (20.9%), and less often in individuals aged ≥80 years (6.0%) compared to 
first eradications (15.4%, 17.2%, and 9.3%, respectively) (Appendix 1 and 2). In 95.3% of all 
eradications a PPI was prescribed on the same day as the antibiotics. The mean and median 
time between first and second eradication was 19 months and 10 months (range 0-110 
months), respectively. The total number of eradications decreased slightly over the study 
period (Table 1). Of all H. pylori eradications, 95.4% were prescribed according to the 
recommended regimen, while 4.7% followed an alternative regimen (Table 1). This 
distribution remained stable throughout the study period, and was similar for both sexes and 
most age groups (Table 1).  
 
Recommended eradication regimen 
The age, sex and calendar year of eradication in individuals who were prescribed the 
recommended regimen followed that of the overall cohort. The combination package was 
used most often, but in children (≤19 years) and elderly (≥80 years) larger proportions, 35.5% 
and 12.8%, respectively, had this regimen prescribed using separate medications (Table 1). 
This was likely due to reductions in doses for children and the elderly. A slight increase of the 
prescription of a combination package was seen over the study period. The incidence of 
recommended H. pylori eradication decreased during the study period, from 193 eradications 
per 100,000 inhabitants in 2006 to 148 eradications per 100,000 inhabitants in 2014 (Figure 
3). 
 
Alternative eradication regimen 
The lowest proportions of alternative eradication treatment were seen in individuals aged 
between 20-29 years (1.7%) and 30-39 years (2.1%). In individuals younger than 20 years, 
3.7% received an alternative eradication. In older adults (≥60 years) more than 6.0% of the 
eradications were according to an alternative regimen (up to 7.8% among individuals aged 
≥80 years) (Table 1). The distribution of alternative regimens per sex and calendar year 
followed that of the overall cohort (Table 1). The incidence of alternative H. pylori 
eradication remained between 7 and 9 eradications per 100,000 inhabitants throughout the 
study period (Figure 3). 
 
Antibiotics used during first eradication 
Recommended eradication regimen 
For the first eradication, the combination package for eradication was prescribed in 84.9% of 
the cases. The separate antibiotics most often prescribed were amoxicillin plus clarithromycin 
(10.9%) (Table 2). Metronidazole was used in only 8 cases (0.006%) for the first eradication. 
 
Alternative eradication regimen 
In total, 15 different antibiotics and 74 different antibiotic combinations were identified 
(including bismuth). The most frequently used antibiotics for an alternative regimen during 
the first eradication episode were ciprofloxacin (2.4%), doxycycline (1.4%), nitrofurantoin 
(0.7%), norfloxacin (0.5%), and erythromycin (0.3%). Combinations of 2 antibiotics that were 
used 100 times or more in total (16 out of 74) are listed in Table 2. Overall, the most common 
alternative antibiotic combinations were amoxicillin and ciprofloxacin, amoxicillin and 
doxycycline, and doxycycline and ciprofloxacin. Bismuth was rarely used (only in 1 first 
eradication episode) (Table 2).  
 
Antibiotics used during repeated eradications 
Recommended eradication regimen 
The recommended eradication regimen was used in 92.7% of all second and third 
eradications. Of these, 85.3% received a combination package, which was similar to the 
proportion in first eradications. The proportion of separately prescribed amoxicillin and 
clarithromycin (7.5%) was lower than in first eradications. Metronidazole was used only 2 
times (0.01%) for a second or third eradication (Table 2).  
 
Alternative eradication regimen 
In total, 12 different antibiotics and 51 different antibiotic combinations were identified for 
repeated eradication therapy. The alternative antibiotics used were similar to those for first 
eradications, adding azithromycin (0.5%) to the often used antibiotics. For most separate 
alternative antibiotics and alternative antibiotic combinations the proportions increased for 
second and third eradications, compared to first eradications (Table 2). 
 
  
Discussion 
This study shows that eradication therapy for H. pylori was common in 2005-2014, although 
the incidence of eradication slowly declined over the same time period. The recommended 
regimen dominated, and only fewer than 5% of all prescriptions consisted of alternative 
combinations of antibiotics, which were especially prescribed among older age groups.  
 
Strengths of this study include the large sample size, population-based design, long study 
period, and the high validity and nationwide completeness of the Prescribed Drug Register.[9] 
Since the exposure information was based on the Prescribed Drug Register, there is no risk of 
recall bias. However, because the register started in 2005 it is not possible to collect 
information on previous eradication episodes in the included individuals, which could have 
led to an incorrect definition of a first eradication episode and a possible underestimation of 
repeated eradication episodes. Another possible limitation is our definition of an eradication 
episode, established a priori in discussions with clinical experts. Unfortunately, no 
information on the indication of treatment was available in the Prescribed Drug Register, so 
we could not verify the validity of our definition. However, the combination package is 
licensed only for H. pylori eradication, so we can be confident about treatment indication for 
these prescriptions. The alternative antibiotic regimens may have been prescribed for other 
bacterial infections, but such error should be limited by the restriction to combined 
prescription of antibiotics and concomitant prescription of a PPI, as well as the restrictions 
regarding dosage and duration of antibiotic use. Combining different types of antibiotics in an 
outpatient setting is rarely indicated. Yet, even if other indications have been misclassified as 
H. pylori eradication, it is likely that this treatment also eradicated H. pylori, especially since 
it was combined with PPIs.[12] Yet, by using these rather strict inclusion criteria (aiming for 
high specificity), we may also have missed some eradication episodes (i.e. decreasing 
sensitivity).  
Unfortunately, no information was available for failure of the H. pylori eradication. It may 
also be questionable if the efficacy of treatment is tested in all individuals receiving H. pylori 
eradication, even if this is recommended.  
 
One previous study has characterized H. pylori eradication in the general population. In that 
Danish population, 28,784 individuals received eradication in 1994-1996 (86% had only 1 
episode compared to 91% in our study).[13] Eradication was defined as a prescription of ulcer 
drugs combined with antibiotics on the same day. There was no separate description of 
recommended or alternative regimens. In our study, most commonly the combination package 
was prescribed to eradicate H. pylori. Reasons not to prescribe the combination package can 
include antibiotic resistance, patient intolerance or allergy to one of the antibiotics or 
unsuitable dosage (e.g. for children, elderly and patients with renal insufficiency).  
 
A sensitivity test is recommended after failed eradication,[5, 14] which apparently is rarely 
performed in practice since this study revealed a substantial rate of additional eradication 
episodes and yet a low proportion of alternative regimens (<5%). Re-infection with H. pylori 
does not seem to be a sufficient explanation for the high number of repeated eradication 
episodes, since re-infection rates in adults are less than 1% in developed countries.[5, 15] 
Suitable antibiotics for second line therapy, or first line in the case of resistance, are 
tetracycline, doxycycline, levofloxacin, tinidazole, rifabutin, and moxifloxacin, possibly in 
combination with bismuth.[5, 16-22] Of these, 4 have been used in our study, predominantly 
doxycycline. Metronidazole was used very rarely, possibly because it has the highest 
proportion of antibiotic resistance for H. pylori in Sweden.[8]  
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Borttagen: Finally, we have no information on 
eradications before the start date of the study, which 
could have led to an incorrect definition of a first 
eradication episode and a possible underestimation 
of repeated eradication episodes.
 These findings raise some concerns about the management of H. pylori in Sweden, because 
they suggest that either no formal diagnosis of H. pylori is confirmed before eradication or 
that an antibiogram is not made in Sweden after a failed eradication, since the same 
combination of antibiotics is used in 92.7% of secondary eradications. An antibiogram should 
guide treatment after initial eradication failure in order to achieve effective eradication and 
prevent (long-term) side effects of systemic antibiotics, e.g. change in microbiome, especially 
since no recent information on antibiotic resistance in Sweden is available. This is important 
for individual patient treatment, and also to prevent antibiotic resistance in the population. 
Thus, there seems to be an urgent need to raise clinical awareness about antibiotic resistance 
in H. pylori and optimize the treatment after eradication failure.  
 
To conclude, over 140,000 individuals (1.5% of the population) have been treated with a 
combination of antibiotics and a PPI that could eradicate H. pylori during the last decade in 
Sweden, although the eradication incidence declined over this period. Eradication mostly 
followed a recommended regimen, including after the first eradication attempt, which 
indicates there may be a need for better awareness about H. pylori antibiotic resistance and 
eradication therapy in Sweden.    
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Table 1. Number of Helicobacter pylori eradications in Sweden (2005-2014) by age, sex and calendar year 
for each different prescribed regimen.   
 
Combination 
package 
Recommended 
regimen 
Alternative 
regimen Total 
 Number (%) Number (%) Number (%) Number (%) 
Total  134,079 (84.9) 16,499 (10.5) 7,337 (4.7) 157,915 (100) 
Age (years) 
    0-19 3,942 (60.8)(2.9)* 2,302 (35.5)(14.0) 241  (3.7)(3.3) 6,485 (4.1) 
20-29 10,916 (89.6)(8.1) 1,068  (8.8)(6.5) 201  (1.7)(2.7) 12,185 (7.7) 
30-39 17,137 (89.5)(12.8) 1,621  (8.5)(9.8) 395  (2.1)(5.4) 19,153 (12.1) 
40-49 21,930 (88.1)(16.4) 2,149 (8.6)(13.0) 801 (3.2)(10.9) 24,880 (15.8) 
50-59 24,207 (86.5)(18.1) 2,425 (8.7)(14.7) 1,361 (4.9)(18.6) 27,993 (17.7) 
60-69 25,494 (84.6)(19.0) 2,767 (9.2)(16.8) 1,864 (6.2)(25.4) 30,125 (19.1) 
70-79 19,245 (83.8)(14.4) 2,359 (10.3)(14.3) 1,375 (6.0)(18.7) 22,979 (14.6) 
≥ 80 11,208 (79.4)(8.4) 1,808 (12.8)(11.0) 1,099 (7.8)(15.0) 14,115 (8.9) 
Sex 
    Male 61,608 (84.4)(46.0) 8,004 (11.0)(48.5) 3,384 (4.6)(46.1) 72,996 (46.2) 
Female 72,471 (85.3)(54.1) 8,495 (10.0)(51.5) 3,953 (4.7)(53.9) 84,919 (53.8) 
Year 
    2005 6,657 (79.0)(5.0) 1,230 (14.6)(7.5) 536 (6.4)(7.3) 8,423 (5.3) 
2006 15,264 (83.1)(11.4) 2,288 (12.5)(13.9) 822 (4.5)(11.2) 18,374 (11.6) 
2007 15,019 (84.1)(11.2) 2,071 (11.6)(12.6) 767 (4.3)(10.5) 17,857 (11.3) 
2008 14,552 (84.2)(10.9) 1,938 (11.2)(11.8) 795 (4.6)(10.8) 17,285 (11.0) 
2009 13,834 (84.5)(10.3) 1,823 (11.1)(11.1) 724 (4.4)(9.9) 16,381 (10.4) 
2010 13,871 (86.2)(10.4) 1,511 (9.4)(9.2) 709 (4.4)(9.7) 16,091 (10.2) 
2011 14,218 (86.1)(10.6) 1,524 (9.2)(9.2) 770 (4.7)(10.5) 16,512 (10.5) 
2012 13,864 (86.0)(10.3) 1,492 (9.3)(9.0) 765 (4.8)(10.4) 16,121 (10.2) 
2013 13,580 (86.4))(10.1) 1,370 (8.7)(8.3) 760 (4.8)(10.4) 15,710 (10.0) 
2014 13,220 (87.2)(9.9) 1,252 (8.3)(7.6) 689 (4.5)(9.4) 15,161 (9.6) 
First 
eradication  119,152 (84.9) 15,350 (10.9) 5889 (4.2) 140,391 (100) 
Second/third 
eradication  13,022 (85.3) 1145 (7.5) 1095 (7.2) 15,262 (100) 
* Numbers in bold are row percentages and numbers in light font are column percentages. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2. Use of the most often prescribed combinations of antibiotics and individual antibiotics for 
Helicobacter pylori eradication. 
 
First 
eradication 
Second/third 
eradication Total (n, %) 
Total 140,391 (100) 15,262 (100) 157,915 (100) 
Combinations 
   Combination package 119,152 (84.9) 13,022 (85.3) 134,079 (84.9) 
Amoxicillin + clarithromycin 15,342 (10.9) 1143 (7.5) 16,553 (10.5) 
Amoxicillin + doxycycline 643 (0.5) 160 (1.0) 834 (0.5) 
Amoxicillin + erythromycin 100 (0.07) 17 (0.1) 125 (0.08) 
Amoxicillin + azithromycin 84 (0.06) 16 (0.1) 102 (0.06) 
Amoxicillin + ciprofloxacin 1739 (1.2) 286 (1.9) 2118 (1.3) 
Amoxicillin + norfloxacin 164 (0.1) 23 (0.2) 191 (0.1) 
Amoxicillin + nitrofurantoin 184 (0.1) 7 (0.05) 193 (0.1) 
Clarithromycin + ciprofloxacin 119 (0.08) 11 (0.07) 131 (0.08) 
Doxycycline + erythromycin 122 (0.09) 20 (0.1) 148 (0.09) 
Doxycycline + ciprofloxacin 538 (0.4) 97 (0.6) 654 (0.4) 
Doxycycline + norfloxacin 214 (0.2) 40 (0.3) 263 (0.2) 
Doxycycline + nitrofurantoin 152 (0.1) 17 (0.1) 172 (0.1) 
Erythromycin + ciprofloxacin 99 (0.07) 12 (0.08) 117 (0.07) 
Azithromycin + ciprofloxacin 119 (0.08) 32 (0.2) 162 (0.1) 
Ciprofloxacin + norfloxacin 124 (0.09) 19 (0.1) 148 (0.09) 
Ciprofloxacin + nitrofurantoin 412 (0.3) 41 (0.3) 454 (0.3) 
Individual antibiotics*^ 
   Amoxicillin  18,322 (13.1) 1726 (11.3) 20,269 (12.8) 
Clarithromycin  15,571 (11.1) 1181 (7.7) 16,828 (10.7) 
Metronidazole  8 (0.006) 2 (0.01) 10 (0.006) 
Tetracyclines 
   Doxycycline 1912 (1.4) 413 (2.7) 2418 (1.5) 
Lymecycline  62 (0.04) 28 (0.2) 96 (0.06) 
Oxytetracycline  1 (0.0007) 0 (0.0) 1 (0.0006) 
Tetracycline  65 (0.05) 39 (0.3) 117 (0.07) 
Tigecycline  1 (0.0007) 0 (0.0) 1 (0.0006) 
Macrolides 
   Erythromycin  444 (0.3) 70 (0.5) 548 (0.3) 
Roxithromycin  73 (0.05) 28 (0.2) 104 (0.07) 
Azithromycin  303 (0.2) 71 (0.5) 393 (0.2) 
Fluoroquinolones 
   Ofloxacin  13 (0.009) 2 (0.01) 15 (0.009) 
Ciprofloxacin  3411 (2.4) 543 (3.6) 4099 (2.6) 
Norfloxacin  739 (0.5) 115 (0.8) 881 (0.6) 
Levofloxacin  93 (0.07) 47 (0.3) 153 (0.1) 
Moxifloxacin 92 (0.07) 20 (0.1) 116 (0.07) 
Nitrofuran derivates 
   Nitrofurantoin  942 (0.7) 86 (0.6) 1041 (0.7) 
Bismuth subcitrate  1 (0.0007) 0 (0.0) 1 (0.0006) 
* Percentages for individual antibiotics do not add up to 100 because the combination package is excluded 
^ All individual antibiotics were part of a combination of at least 2 antibiotics dispensed on the same date, 
including a PPI within a time window of 60 days before or 5 days after antibiotics prescription. 
Figure 1: Flowchart of the construction of the cohort being prescribed eradication for 
Helicobacter pylori  
  
7,522,991 unique individuals 
Excluded because no prescription of 
PPI/antibiotics/combination 
package/bismuth (n=2,291,292) 
5,231,699 unique individuals 
(120,548 with combination package, 
4,308,208 with antibiotics, 1,487,717 
with PPI, 65 with bismuth) Excluded because no relevant 
antibiotic/combination package code 
(n=876,494) 
4,355,205 unique individuals with at 
least 1 prescription of antibiotics or 
combination package 
1,502,059 unique individuals with at 
least 1 prescription of PPI or 
combination package 
998,351 unique individuals 
Excluded episodes with <2 prescriptions 
for different antibiotics (and no 
combination package) (n=503,708) 
 
151,261 unique individuals 
Excluded because extremely high 
antibiotic dosage for 1 antibiotic 
(DDD>21) on same day and no 
prescription for combination package (no 
other combination of antibiotics in lower 
dosages on same date left) (n=847,090) 
150,702 unique individuals 
Excluded because no PPI/combination 
package code (n=2,853,146) 
Excluded those with ≥50 unique antibiotic 
prescriptions during study period (n=559) 
 
Excluded because no 2 antibiotics on the 
same day in combination with PPI in time 
window (n=10,311) 
 140,391 unique individuals 
- 157,915 episodes 
 
PPI: proton pump inhibitor, DDD: defined daily dose 
  
 
Figure 2. Number of Helicobacter pylori eradications in relation to sex and age. 
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Appendix 1. Number of Helicobacter pylori eradications in Sweden (2005-2014) by age, sex and calendar 
year for each different prescribed regimen for first eradications.   
 
Combination 
package 
Recommended 
regimen 
Alternative 
regimen Total 
 Number (%) Number (%) Number (%) Number (%) 
Total  119,152 (84.9) 15,297 (10.9) 5,942 (4.2) 140,391 (100) 
Age (years) 
    0-19 3,657 (61.4)(3.1)* 2,116 (35.5)(13.8) 184 (3.1)(3.1) 5,957 (4.2) 
20-29 10,009 (89.5)(8.4) 998 (8.9)(6.5) 171 (1.5)(2.9) 11,178 (8.0) 
30-39 15,279 (89.5)(12.8) 1,482 (8.7)(9.7) 313 (1.8)(5.3) 17,074 (12.2) 
40-49 18,985 (88.1)(15.9) 1,948 (9.0)(12.7) 623 (2.9)(10.5) 21,556 (15.4) 
50-59 20,892 (86.5)(17.5) 2,213 (9.2)(14.5) 1,051 (4.4)(17.7) 24,156 (17.2) 
60-69 22,482 (84.7)(18.9) 2,563 (9.7)(16.8) 1,489 (5.6)(25.1) 26,534 (18.9) 
70-79 17,440 (83.7)(14.6) 2,245 (10.8)(14.7) 1,157 (5.6)(19.5) 20,842 (14.9) 
≥ 80 10,408 (79.5)(8.7) 1,732 (13.2)(11.3) 954 (7.3)(16.1) 13,094 (9.3) 
Sex 
    Male 55,105 (84.4)(46.3) 7,432 (11.4)(48.6) 2,737 (4.2)(46.1) 65,274 (46.5) 
Female 64,047 (85.3)(53.8) 7,865 (10.5)(51.4) 3,205 (4.3)(53.9) 75,117 (53.5) 
Year 
    2005 6,504 (79.1)(5.5) 1,211 (14.7)(7.9) 511 (6.2)(8.6) 8,226 (5.9) 
2006 14,225 (83.2)(11.9) 2,180 (12.8)(14.3) 699 (4.1)(11.8) 17,104 (12.2) 
2007 13,504 (84.3)(11.3) 1,920 (12.0)(12.6) 600 (3.7)(10.1) 16,024 (11.4) 
2008 12,945 (84.2)(10.9) 1,777 (11.6)(11.6) 645 (4.2)(10.9) 15,367 (11.0) 
2009 12,267 (84.4)(10.3) 1,693 (11.7)(11.1) 578 (4.0)(9.7) 14,538 (10.4) 
2010 12,214 (86.3)(10.3) 1,366 (9.7)(8.9) 566 (4.0)(9.5) 14,146 (10.1) 
2011 12,324 (86.1)(10.3) 1,369 (9.6)(9.0) 628 (4.4)(10.6) 14,321 (10.2) 
2012 11,982 (85.9)(10.1) 1,359 (9.7)(8.9) 607 (4.4)(10.2) 13,948 (9.9) 
2013 11,779 (86.4))(9.9) 1,257 (9.2)(8.2) 594 (4.4)(10.0) 13,630 (9.7) 
2014 11,408 (87.2)(9.6) 1,165 (8.9)(7.6) 514 (3.9)(8.7) 13,087 (9.3) 
* Numbers in bold are row percentages and numbers in light font are column percentages. 
 
 
 
 
 
 
 
 
 
 
Appendix 2. Number of Helicobacter pylori eradications in Sweden (2005-2014) by age, sex and calendar 
year for each different prescribed regimen for second and third eradications.   
 
Combination 
package 
Recommended 
regimen 
Alternative 
regimen Total 
 Number (%) Number (%) Number (%) Number (%) 
Total 13,022 (85.3) 1,135 (7.4) 1,105 (7.2) 15,262 (100) 
Age (years) 
    0-19 277 (55.3)(2.1)* 178 (35.5)(15.7) 46 (9.2)(4.2) 501 (3.3) 
20-29 857 (90.2)(6.6) 68 (7.2)(6.0) 25 (2.6)(2.3) 950 (6.2) 
30-39 1,703 (89.3)(13.1) 132 (6.9)(11.6) 73 (3.8)(6.6) 1,908 (12.5) 
40-49 2,555 (88.8)(19.6) 183 (6.4)(16.1) 140 (4.9)(12.7) 2,878 (18.9) 
50-59 2,745 (86.0)(21.1) 198 (6.2)(17.4) 249 (7.8)(22.5) 3,192 (20.9) 
60-69 2,550 (83.7)(19.6) 192 (6.3)(16.9) 305 (10.0)(27.6) 3,047 (20.0) 
70-79 1,602 (85.5)(12.3) 110 (5.9)(9.7) 162 (8.6)(14.7) 1,874 (12.3) 
≥ 80 733 (80.4)(5.6) 74 (8.1)(6.5) 105 (11.5)(9.5) 912 (6.0) 
Sex 
    Male 5,689 (84.5)(43.7) 542 (8.1)(47.8) 501 (7.4)(45.3) 6,732 (44.1) 
Female 7,333 (86.0)(56.3) 593 (7.0)(52.3) 604 (7.1)(54.7) 8,530 (55.9) 
Year 
    2005 152 (79.6)(1.2) 19 (10.0)(1.7) 20 (10.5)(1.8) 191 (1.3) 
2006 983 (82.0)(7.6) 108 (9.0)(9.5) 108 (9.0)(9.8) 1,199 (7.9) 
2007 1,399 (83.6)(10.7) 147 (8.8)(13.0) 127 (7.6)(11.5) 1,673 (11.0) 
2008 1,421 (83.6)(10.9) 153 (9.0)(13.5) 125 (7.4)(11.3) 1,699 (11.1) 
2009 1,389 (85.4)(10.7) 121 (7.4)(10.7) 116 (7.1)(10.5) 1,626 (10.7) 
2010 1,435 (85.8)(11.0) 136 (8.1)(12.0) 101 (6.0)(9.1) 1,672 (11.0) 
2011 1,627 (86.1)(12.5) 141 (7.5)(12.4) 121 (6.4)(11.0) 1,889 (12.4) 
2012 1,580 (86.2)(12.1) 127 (6.9)(11.2) 127 (6.9)(11.5) 1,834 (12.0) 
2013 1,513 (86.8))(11.6) 104 (6.0)(9.2) 126 (7.2)(11.4) 1,743 (11.4) 
2014 1,523 (87.7)(11.7) 79 (4.6)(7.0) 134 (7.7)(12.1) 1,736 (11.4) 
* Numbers in bold are row percentages and numbers in light font are column percentages. 
 
